• Je něco špatně v tomto záznamu ?

Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats

Zuzana Honetschlägerová, Alexandra Sporková, Libor Kopkan, Zuzana Husková, Sung H. Hwang, Bruce D. Hammock, John D. Imig, Herbert J. Kramer, Petr Kujal, Zdenka Vernerová, Věra Č. Chábová, Vladimír Tesař, Luděk Červenka

. 2011 ; 29 (8) : 1590-1601.

Jazyk angličtina Země Velká Británie

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12022390

Grantová podpora
NS9699 MZ0 CEP - Centrální evidence projektů
NS10500 MZ0 CEP - Centrální evidence projektů
NS9703 MZ0 CEP - Centrální evidence projektů
NS10499 MZ0 CEP - Centrální evidence projektů

OBJECTIVE: In the present study, we compared the effects of treatment with the novel soluble epoxide hydrolase (sEH) inhibitor (c-AUCB) with those of the AT1 receptor antagonist losartan on blood pressure (BP), autoregulation of renal blood flow (RBF) and on glomerular filtration rate (GFR) and the pressure-natriuresis relationship in response to stepwise reduction in renal arterial pressure (RAP) in Cyp1a1-Ren-2 transgenic rats. METHODS: Hypertension was induced in Cyp1a1-Ren-2 rats through dietary administration for 11 days of the natural xenobiotic indole-3-carbinol (I3C) which activates the renin gene. Treatment with c-AUCB and losartan was started 48 h before initiating administration of the diet containing I3C. Rats were prepared for renal functional studies to evaluate in-vivo renal autoregulatory efficiency when RAP was gradually decreased by an aortic clamp. RESULTS: I3C administration resulted in the development of severe hypertension which was associated with markedly lower basal RBF and GFR and substantially impaired autoregulatory efficiency as well as a suppression of the pressure-natriuresis relationship when compared with noninduced rats. Treatment with c-AUCB significantly decreased BP, improved autoregulatory efficiency of RBF and GFR and the slope of pressure-natriuresis relationship. Treatment with losartan completely prevented the impaired autoregulation and pressure-natriuresis relationship as well as the development of hypertension in I3C-induced rats. CONCLUSION: Our present findings indicate that chronic treatment with the sEH inhibitor c-AUCB substantially attenuates the development of malignant hypertension in I3C-induced rats likely via improvement of the renal autoregulatory efficiency and the pressure-natriuresis relationship.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12022390
003      
CZ-PrNML
005      
20190430165304.0
007      
ta
008      
120806s2011 xxk f 000 0#eng||
009      
AR
024    7_
$a 10.1097/HJH.0b013e328349062f $2 doi
035    __
$a (PubMed)21720266
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Honetschlägerová, Zuzana $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center of Cardiovascular Research, Prague, Czech Republic
245    10
$a Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats / $c Zuzana Honetschlägerová, Alexandra Sporková, Libor Kopkan, Zuzana Husková, Sung H. Hwang, Bruce D. Hammock, John D. Imig, Herbert J. Kramer, Petr Kujal, Zdenka Vernerová, Věra Č. Chábová, Vladimír Tesař, Luděk Červenka
520    9_
$a OBJECTIVE: In the present study, we compared the effects of treatment with the novel soluble epoxide hydrolase (sEH) inhibitor (c-AUCB) with those of the AT1 receptor antagonist losartan on blood pressure (BP), autoregulation of renal blood flow (RBF) and on glomerular filtration rate (GFR) and the pressure-natriuresis relationship in response to stepwise reduction in renal arterial pressure (RAP) in Cyp1a1-Ren-2 transgenic rats. METHODS: Hypertension was induced in Cyp1a1-Ren-2 rats through dietary administration for 11 days of the natural xenobiotic indole-3-carbinol (I3C) which activates the renin gene. Treatment with c-AUCB and losartan was started 48 h before initiating administration of the diet containing I3C. Rats were prepared for renal functional studies to evaluate in-vivo renal autoregulatory efficiency when RAP was gradually decreased by an aortic clamp. RESULTS: I3C administration resulted in the development of severe hypertension which was associated with markedly lower basal RBF and GFR and substantially impaired autoregulatory efficiency as well as a suppression of the pressure-natriuresis relationship when compared with noninduced rats. Treatment with c-AUCB significantly decreased BP, improved autoregulatory efficiency of RBF and GFR and the slope of pressure-natriuresis relationship. Treatment with losartan completely prevented the impaired autoregulation and pressure-natriuresis relationship as well as the development of hypertension in I3C-induced rats. CONCLUSION: Our present findings indicate that chronic treatment with the sEH inhibitor c-AUCB substantially attenuates the development of malignant hypertension in I3C-induced rats likely via improvement of the renal autoregulatory efficiency and the pressure-natriuresis relationship.
650    _2
$a blokátory receptorů AT1 pro angiotensin II $x farmakologie $7 D047228
650    _2
$a zvířata $7 D000818
650    _2
$a krevní tlak $x účinky léků $x fyziologie $7 D001794
650    _2
$a cytochrom P-450 CYP1A1 $x genetika $7 D019363
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a inhibitory enzymů $x farmakologie $7 D004791
650    _2
$a epoxid hydrolasy $x antagonisté a inhibitory $7 D004851
650    _2
$a hodnoty glomerulární filtrace $x účinky léků $x fyziologie $7 D005919
650    _2
$a hypertenze maligní $x chemicky indukované $x patofyziologie $x prevence a kontrola $7 D006974
650    _2
$a indoly $x škodlivé účinky $7 D007211
650    _2
$a ledviny $x krevní zásobení $x patologie $x patofyziologie $7 D007668
650    _2
$a nemoci ledvin $x patofyziologie $x prevence a kontrola $7 D007674
650    _2
$a losartan $x farmakologie $7 D019808
650    _2
$a natriuréza $x účinky léků $x fyziologie $7 D009318
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani transgenní $7 D055647
650    _2
$a regionální krevní průtok $x účinky léků $x fyziologie $7 D012039
650    _2
$a renin $x genetika $7 D012083
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sporková, Alexandra $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center of Cardiovascular Research, Prague, Czech Republic
700    1_
$a Kopkan, Libor $7 xx0107287 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center of Cardiovascular Research, Prague, Czech Republic
700    1_
$a Husková, Zuzana, $d 1978- $7 xx0074206 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center of Cardiovascular Research, Prague, Czech Republic
700    1_
$a Hwang, Sung H. $u Department of Entomology and UCD Cancer Center, University of California, Davis, Davis, California, USA
700    1_
$a Hammock, Bruce D. $u Department of Entomology and UCD Cancer Center, University of California, Davis, Davis, California, USA
700    1_
$a Imig, John D. $u Department of Pharmacology and Toxicology, Medical College of Wisconsin, Wisconsin, USA
700    1_
$a Kramer, Herbert J. $u Section of Nephrology, Medical Policlinic, Department of Medicine, University Bonn, Bonn, Germany
700    1#
$a Kujal, Petr $7 xx0244311 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Pathology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Vernerová, Zdenka, $d 1960-2020 $7 jo2002104672 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Pathology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Čertíková-Chábová, Věra $7 xx0095872 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Tesař, Vladimír, $d 1957- $7 jn20000402349 $u Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Červenka, Luděk, $d 1967- $7 xx0037105 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Physiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00002723 $t Journal of hypertension $x 1473-5598 $g Roč. 29, č. 8 (2011), s. 1590-1601
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21720266 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120806 $b ABA008
991    __
$a 20190430165349 $b ABA008
999    __
$a ok $b bmc $g 944303 $s 779687
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 29 $c 8 $d 1590-1601 $i 1473-5598 $m Journal of hypertension $n J Hypertens $x MED00002723
GRA    __
$a NS9699 $p MZ0
GRA    __
$a NS10500 $p MZ0
GRA    __
$a NS9703 $p MZ0
GRA    __
$a NS10499 $p MZ0
LZP    __
$a Pubmed-20120806/12/01

Najít záznam

Citační ukazatele

Možnosti archivace